Clinical trials: Postmenopausal Symptoms
Hot Flashes
Phase 2 Study of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms
This study evaluates the efficacy, safety, tolerability, and pharmacokinetics of once daily SJX-653 in postmenopausal women with moderate to severe VMS.
- Trial name
- NCT04278872
- Testing
- SJX-653
- Where
- 22 sites in Belgium, Germany and 2 more
- Volunteers
- 13 people
- Sponsor
- Sojournix, Inc.
Menopause
Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women
To determine whether treatment with ESTRATEST® H.S. Tablets is superior to treatment with esterified estrogens tablets
- Trial name
- NCT00141570
- Testing
- esterified estrogens 0.625 mg and methyltestosterone 1.25 mg
- Where
- 77 sites in United States
- Volunteers
- 350 people
- Sponsor
- Solvay Pharmaceuticals
Depressive Symptoms, Urinary Incontinence
BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and Postmenopausal Women
The goal of this clinical trial is to evaluate if the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices is able to improve depressive symptoms and sexual function in women who are perimenopausal or…
- Conditions
- Depressive Symptoms, Urinary Incontinence, Sexual Dysfunction
- Trial name
- NCT07413705
- Testing
- EXOMIND (BTL-699-2) Active Treatment, EMSELLA (HPM-6000UF) ActiveTreatment
- Where
- 3 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- BTL Industries Ltd.
Breast Neoplasms
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
The study is designed to compare the clinical benefit following treatment with letrozole in combination with PD-0332991 versus letrozole in combination with placebo in postmenopausal women with ER(+)/HER2(-) advanced breast…
- Trial name
- NCT01740427
- Testing
- PD-0332991, Letrozole
- Where
- 305 sites in United States, Australia and 16 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
Breast Cancer, Cognitive Symptom
MBSR During AI Therapy for Breast Cancer
This study will use non-invasive neuroimaging (i.e., MRI) to examine whether Mindfulness-Based Stress Reduction (MBSR) improves neural markers of cognitive function for postmenopausal women taking aromatase inhibitor (AI) therapy…
- Trial name
- NCT03253627
- Testing
- Health Enhancement Program, Mindfulness-Based Stress Reduction
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- New York University
Breast Neoplasms
Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer
This is an international, multicentre, double-blind, controlled, randomized phase II study comparing the efficacy and safety of fulvestrant in combination with palbociclib versus fulvestrant plus placebo in postmenopausal women…
- Trial name
- FLIPPER (NCT02690480)
- Testing
- PD-0332991 (Palbociclib), Fulvestrant
- Where
- 32 sites in Ireland, Spain
- Volunteers
- 189 people
- Sponsor
- Spanish Breast Cancer Research Group